Blueprint Medicines (BPMC) Misses Q1 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall St falls as oil ticks up, yields rise ahead of US-China summit
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil holds near two-week lows while diesel cracks hit record
Blueprint Medicines Reports First Quarter 2019 Financial Results
May 9, 2019 7:00 AM EDTCAMBRIDGE, Mass., May 9, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today reported financial results and provided a business update for the quarter ended March 31, 2019.
"Based on significant clinical and regulatory progress in the first quarter, we accelerated multiple programs and advanced our '2020 Blueprint' strategy to transform Blueprint Medicines into a... More
